## Krzysztof Dyrbus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7814296/publications.pdf

Version: 2024-02-01

759233 888059 19 612 12 17 citations h-index g-index papers 20 20 20 815 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels. American Journal of Cardiology, 2006, 97, 899-904.	1.6	101
2	Inclisiran—New hope in the management of lipid disorders?. Journal of Clinical Lipidology, 2020, 14, 16-27.	1.5	80
3	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.9	78
4	Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease. BMC Cardiovascular Disorders, 2013, 13, 113.	1.7	64
5	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 2021, 166, 105499.	7.1	62
6	Impact of chronic total occlusion artery on 12-month mortality in patients with non-ST-segment elevation myocardial infarction treated by percutaneous coronary intervention (From the PL-ACS) Tj ETQq0 0 0	rgB <b>T.†</b> Over	rloc <b>k</b> 310 Tf 50
7	Comparison of Outcomes of Direct Stenting Versus Stenting After Balloon Predilation in Patients With Acute Myocardial Infarction (DIRAMI). American Journal of Cardiology, 2007, 100, 798-805.	1.6	31
8	The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis, 2019, 288, 33-41.	0.8	28
9	Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes $\hat{a} \in \mathbb{C}$ Data from the TERCET registry with 19,287 patients. Pharmacological Research, 2019, 139, 460-466.	7.1	28
10	Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacological Research, 2018, 132, 204-210.	7.1	20
11	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. Atherosclerosis, 2021, 333, 16-23.	0.8	19
12	Intravascular Lithotripsy for the Treatment of Stent Underexpansion: The Multicenter IVL-DRAGON Registry. Journal of Clinical Medicine, 2022, 11, 1779.	2.4	16
13	Extreme cardiovascular risk—do we need a new risk category?. European Heart Journal, 2022, 43, 1784-1786.	2.2	11
14	Comparison of modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas in predicting long-term outcomes in patients undergoing stent implantation due to stable coronary artery disease. Clinical Research in Cardiology, 2014, 103, 569-576.	3.3	10
15	Telehealth visits in a tertiary cardiovascular centre as a response of the healthcare system to the pandemic of SARS-CoV-2 in Poland. Polish Archives of Internal Medicine, 2020, 130, 700-703.	0.4	6
16	Hemorrhagic Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 426-427.	2.8	3
17	The usefulness of left ventricular endomyocardial biopsy in clinical decision making in patients with unexplained heart failure. Kardiochirurgia I Torakochirurgia Polska, 2019, 16, 173-179.	0.1	О
18	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅci PTDL, 2021, 57, 1-99.	0.1	0

#	Article	IF	CITATIONS
19	Long-term results of 11,021 patients with chronic coronary syndrome and after coronarography (from the PRESAGE Registry). Polish Archives of Internal Medicine, 2020, 130, 1043-1052.	0.4	0